CRISPR Biotech Caribou Biosciences Adds Steven Kanner to Exec Team

Caribou Biosciences has brought on Steven Kanner as the Berkeley, CA, biotech’s new chief scientific officer. Caribou develops applications for the CRISPR-Cas gene editing technology. Kanner joins Caribou from Pasadena, CA-based Arrowhead Pharmaceuticals (NASDAQ: [[ticker:ARWR]]), where he was vice president of discovery biology. His experience also includes positions at Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), Astex Pharmaceuticals (NYSE: [[ticker:ASTX]]), and Agensys, now part of Astellas Pharma.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan